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ABSTRACT  
Utilizing metal-organic frameworks (MOFs) as a biological carrier can lower the amount of 
active pharmaceutical ingredient (API) required in cancer treatments to provide a more 
efficacious therapy. In this work, we have developed a temperature treatment process for 
delaying the release of a model drug compound from the pores of NU-1000 and NU-901, while 
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taking care to utilize these MOFs’ large pore volume and size to achieve exceptional model drug 
loading percentages over 35 wt.%. Video-rate super-resolution microscopy reveals movement of 
MOF particles when located outside of the cell boundary, and their subsequent immobilization 
when taken up by the cell. Through the use of optical sectioning structured illumination 
microscopy (SIM), we have captured high-resolution 3D images showing MOF uptake by HeLa 
cells over a 24 h period. We found that addition of a model drug compound into the MOF and 
the subsequent temperature treatment process does not affect the rate of MOF uptake by the cell. 
Endocytosis analysis revealed that MOFs are internalized by active transport, and that inhibiting 
the cavaeloe-mediate pathway significantly reduced cellular uptake of MOFs. Encapsulation of 
an anticancer therapeutic, alpha-cyano-4-hydroxycinnamic acid (α-CHC), and subsequent 
temperature treatment produced loadings of up to 81 wt.% and demonstrated efficacy at killing 
cells beyond the burst release effect. 
Introduction 
Cancer is a major health problem worldwide. In 2012, there were more than 14 million cases of 
cancer diagnosed, and over the next two decades, this number is expected to grow by 70%.1 In 
the United States of America, it is expected that 1 in 2.5 people will develop some form of 
cancer during their lifetime.2 Patients diagnosed with cancer rely on active pharmaceutical 
ingredients (APIs) to eliminate the disease, reduce side effects, and prolong their lives. However, 
most APIs suffer from low stability, poor solubility, and an inability to bypass biological 
barriers.3 One critical problem of compounds investigated in early-stage API development is that 
they present such short half-lives that are unsuitable for use as a pharmacological treatment, and 
therefore are not even worth funding through clinical trials.4,5 Furthermore, current treatments 
are mostly untargeted and result in non-specific biodistribution, meaning that healthy cells are 
3 
 
killed as a negative side-effect of the treatment.6 Additionally, the probability of patients 
following treatment through to completion is lower due to the undesirable side-effects, such as 
lower energy levels, as well as patients’ previous health beliefs and attitudes, experiences with 
pharmacological therapies, and lack of overall motivation.7 Therefore, the ability to implement a 
drug delivery system that could overcome inherent API limitations would provide a highly 
beneficial resource to pharmaceutical products and extend the capabilities of treatments currently 
in development.8    
Different types of drug delivery systems are being researched to accomplish controlled, 
sustained release. To be effective, the system must: i) protect and target the APIs such that they 
reach their desired location, ii) last for extended periods of time to minimalize the discomfort and 
harmful side effects of systemic administration, and iii) ensure that the APIs are efficacious upon 
reaching their desired target.3,9 The most common systems presently in use are organic, including 
lipids, hydrogels, micelles, and other forms of polymeric nanocarriers.3,10–12 These systems have 
several shortcomings, including poor control of drug release and relatively low loading 
capacities: for example busulfan in liposome and polymer nanocarriers have loadings of only 5-6 
wt.%.13–15   
Metal-organic frameworks (MOFs), one of the most exciting developments in recent porous-
materials science, are a class of porous hybrid self-assembling solids containing metal clusters 
connected by organic linkers. MOFs have been applied to catalysis,16–19 gas storage and 
separation,20–23 ion exchange,24,25 and sensors26,27 because of their potential for flexible rational 
design.28 This has been exploited extensively to create structures of highly diverse composition 
(e.g. linkers varying from amines to polycarboxylates to imidazolates), shape (e.g. cubic, 
hexagonal, and prismatic geometries), and pore size (upwards of 6 nm).3,29 Recently, MOFs have 
4 
 
emerged in the field of biomedicine.3,30–32 They are of particular interest in biological delivery 
applications because of their highly tunable surface functionalities and ability to encapsulate high 
loadings of active molecules,29,33 requiring less API to achieve the necessary pharmaceutical 
effect and overcoming the drawbacks of organic drug delivery systems. In addition, many MOFs 
are also confirmed to be non-toxic.3,34 Recent advances in this area include the exploration of 
iron-based MOFs for delivery of anti-tumoral and anti-HIV drugs, and zirconium-based MOFs 
for co-delivery of cisplatin and pooled siRNAs.33,35 In particular, the low stability of some MOFs 
in aqueous solvents can be seen as an advantage for drug delivery systems since their breakdown 
can prevent accumulation in the body, ensuring lower cytotoxicity.36  
We have, among others, utilized Zr-based MOFs in the past because of their high level of 
biocompatibility and their relatively high mechanical, thermal, and chemical stability.36–40 Some 
of these structures, particularly those with longer linkers, have attracted significant attention in 
the last years due to the possibility of developing mesoporosity while keeping an optimal 
stability.41 In particular, NU-1000 and NU-901 are two MOFs formed by a parent-framework 
node of octahedral Zr6-cluster capped by eight μ3-OH ligands, where eight of the twelve edges 
are linked to TBAPy ligands (Supplementary Information, Figure S1). In NU-1000, the 3D 
structure can be described as 2D Kagome sheets stacked by TBAPy ligands;41 from the N2 
adsorption isotherm at 77 K it presents a BET area of 2320 m2g−1 and a total pore volume of 1.4 
cm3g−1 (Figure S2). In NU-901, the 3D structure can be described as stacked diamond-shaped 
channels;42 from the N2 adsorption isotherm at 77 K it presents a BET area of 2500 m
2g−1 and a 
total pore volume of 1.29 cm3g−1 (Figure S2). The largest pore dimension for NU-1000 and NU-
901, respectively, is 30 Å and 27 Å, creating large pore cavities that are advantageous for high 
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internal loading capacities. The thermal gravimetric analysis (TGAs) of these two Zr-based 
MOFs are shown in Figure S3, demonstrating their high thermal stability. 
While NU-1000 and NU-901 are hypothesized to reach extremely high loading capacities due 
to their large pore volumes, there has been concern about the burst release effect – an 
undesirable phenomenon where most of the load escapes within a short time, causing potential 
toxicity and lower efficacy.43 In previous works, we investigated the use of ball-milling to 
amorphisize a MOF as a way of entrapping a model drug to delay release.36,37 In this work, we 
now present an improved method that can handle mechanically fragile payloads. We have 
developed a mild temperature treatment protocol that causes partial pore collapse of NU-1000 
and NU-901, thus delaying the release of a model compound, calcein, as well as the anticancer 
therapeutic alpha-Cyano-4-hydroxycinnamic acid (α-CHC). 
To better understand the release of MOF payload in vitro, we have utilized structured 
illumination microscopy (SIM) to visualize the interaction of MOFs with live cells at an 
unprecedented level of detail. SIM is a super-resolution microscopy technique that is able to 
capture images with a resolution of 100nm – twice the resolution of a conventional diffraction-
limited instrument – and provide optical sectioning, which facilitates three-dimensional image 
reconstruction.44 Furthermore, SIM can image faster than any other super-resolution microscopy 
technique,45 at frame rates exceeding 10 Hz per color channel.46,47 We believe this is the first 
study of MOFs to employ super-resolution microscopy, and the first to utilize optical sectioning 
SIM to observe any nanocarrier in 3D. Through this work, we show the potential of engineering 
an optimal MOF nanosystem capable of providing long-term controlled release, as well as super-
resolution methods for verifying in vitro phenomena. 
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Results & Discussion 
MOF loading and temperature treatment 
Figure 1 shows the powder X-ray diffraction (PXRD) patterns of both NU-901 and NU-1000, 
demonstrating excellent agreement with the simulated patterns. We loaded calcein, a model 
compound, into both MOFs. Calcein is a good model drug candidate as it is hydrophilic and has 
minimal membrane permeability without a vehicle.36 It is also similar in size to doxorubicin, a 
widely-used anticancer therapeutic. Furthermore, its intrinsic fluorescence allows for easy 
detection using microscopy. Post loading, the critical Bragg peaks were maintained, confirming 
the stability of the MOF structure (see Figure S4a for Pawley fitting of the PXRD patterns). 
These post-loading samples are referred to as cal@MOF. It is worth noting that the PXRD of 
calcein is amorphous (Figure S4b), and that the slight broadening of the peaks is most likely a 
result of the loading process, which takes place in aqueous solvent and leads to small levels of 
decrystallization of the MOF. After calcein loading, we used a temperature treatment process at 
180 ̊C on loaded samples in order to induce partial collapse of the MOF porosity around calcein 
and entrap it within the structure. We hypothesize that this should lead to slower release and 
avoid the burst release effect. The temperature-treated samples are referred to as cal@t.t.MOF. 
After the temperature treatment protocol, the critical 2θ peaks of the PXRD patterns are 
significantly broader and peak intensity is noticeably decreased compared to those of the 
crystalline-loaded sample (cal@MOF). This is in contrast with previous mechanical 
amorphization work where the peaks have completely disappeared,36 suggesting that, in our 
temperature-treated MOF, the long range order was not completely destroyed by the pore 
collapse.  
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Figure 1. Powder X-ray diffraction (PXRD) patterns of a) synthesized NU-1000, cal@NU-1000, and 
cal@t.t.NU-1000 compared with the calculated one for NU-1000 and b) synthesized NU-901, cal@NU-
901, and cal@t.t.NU-901 compared with the calculated one for NU-901. 
To ensure calcein’s stability during the temperature treatment process, NMR was run on 
digested loaded NU-901 samples pre and post treatment (Figure S5 and S6). The NMR-spectra 
reveals that the peaks attributed to calcein were not perturbed, suggesting no significant chemical 
changes to the model drug occur after heat treatment; analogous trends were observed with NU-
1000. Additionally, the TGA for calcein (Figure S7) shows clearly that that any thermal 
degradation of the compound occurs at temperatures above 200°C, well above the treatment 
temperature. 
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Calcein-loaded NU-901 crystalline and temperature-treated samples had loadings of 37.0 ± 0.7 
wt.% and 38.0 ± 0.2 wt.%, respectively. The loadings of the crystalline and temperature-treated 
NU-1000 samples, obtained through UV-Vis absorption measurement at 498 nm, were 41.6 ± 
1.1 wt.% and 19.7 ± 0.4 wt.%, respectively. The loadings of these materials far exceeds the 5 
wt.% loading of our previous work by mechanical amorphisation.36 In order to prove that the 
loaded calcein is located in the internal porosity of the MOFs, we ran N2 isotherms on calcein-
loaded NU-1000 and NU-901 samples (Figure S8). We observed a substantial decrease in the 
BET area from 2320 m2/g to 520 m2/g for NU-1000 to cal@NU-1000, and from 2500 m2/g to 
200 m2/g for NU-901 compared to cal@NU-901. Additionally, the shape of the isotherms was 
affected. As Figure S8a shows, the mesoporous step that occurs around relative pressure of 0.3 in 
NU-1000 has been shifted to a lower relative pressure in cal@NU-1000. We attribute this to 
calcein filling the inner walls of the mesoporous channels and allowing for complete adsorption 
of nitrogen in these channels at lower relative pressures. Furthermore, the relative intensity of the 
mesoporous step has decreased, which also suggests that calcein is loaded internally within the 
MOF. In Figure S8b, the small mesoporous step around 0.3 relative pressure has completely 
disappeared, which suggests that calcein has filled the MOF’s porosity. Altogether, this 
demonstrates that calcein is adsorbed in the internal porosity in both MOFs. 
From these loaded samples, we performed a release study in phosphate buffered saline (PBS) 
to evaluate the mass of calcein delivered. Figure 2 shows the release curves of calcein from both 
crystalline and temperature-treated samples, for both NU-1000 and NU-901. Although in the 
long-term the release profiles are similar, the critical first two days exhibit differences in the rate 
of calcein release between crystalline and temperature-treated samples for both NU-1000 and 
NU-901. The release profiles of t.t.NU-1000 show a delay of up to 7 days compared to the 
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crystalline NU-1000. In the first 4 hours they show a release of ca. 28 wt.% and 10 wt.% for NU-
1000 and t.t.NU-1000, respectively (Figure 2a). These differences increase to 60 wt.% and 34 
wt.% after 1 day; t.t.NU-1000 still retains slower release after 2 days, where crystalline sample 
calcein release is ca. 65 wt.% compared to ca. 44 wt.%. Complete release of calcein from both 
crystalline and temperature-treated samples of NU-1000 is not complete until about 7 weeks. The 
overlap of these two profiles does not occur until approximately 7 days. NU-901 shows similar 
release trends but the effect is not as pronounced as in the case with NU-1000 (Figure 2b). To 
further investigate this difference, we performed additional molecular mechanics calculations for 
both NU-901 and NU-1000, and calculated their mechanical properties. Interestingly, all primary 
mechanical properties such as bulk modulus, shear modulus and direction-dependent Young’s 
moduli consistently show larger values for NU-901 suggesting a more robust structure (Table 
S1). We attribute the stronger framework integrity in NU-901 to the less dramatic effect of the 
temperature treatment. After the first 4 h, the crystalline form has released ca. 21 wt.% of its 
contents, compared with ca. 16 wt.% in t.t.NU-901. These differences increase to ca. 54 wt.% 
and ca. 47 wt.% after 1 day; t.t.NU-901 slightly delays the release of calcein up to 2 days before 
its profile crossed that of the crystalline sample. Complete release of calcein from both 
crystalline and temperature-treated samples of NU-901 is not complete until close to 3 weeks.  
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Figure 2. Calcein release from a) crystalline NU-1000 (black closed circles) and t.t.NU-1000 (red open 
circles), and b) crystalline NU-901 (black closed circles) and t.t.NU-901 (red open circles). Insets of both 
images show first few days of release study. 
The crystalline release curves for both NU-901 and NU-1000 already show a substantial 
improvement on slowing the rate of release compared to previous studies of other crystalline 
MOFs.13,30,48 In particular, Horcajada et al. showed that the complete release of the 
anticancer/antiviral drugs azidothymidine triphosphate, and cidofovir from crystalline MIL-100 
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occurred within 5 days and of doxorubicin in 12 days.13 They also observed full release of 
ibuprofen within 3 and 6 days for MIL-100 and MIL-101, respectively.30 We compared our 
release rates to UiO-66, another Zr-based MOF, where there is ca. 75 wt.% of calcein release 
from UiO-66 in just 6 hours.36 This is much higher than the percentage released from our 
crystalline NU-901 or NU-1000 at 6 hours – ca. 28 wt.% and 33 wt.%, respectively.  Overall, the 
temperature treatment slows down the early release of calcein from the two MOFs studies. The 
effect of this process is less dramatic than that of mechanical amorphization, which extends the 
release of calcein up to 30 days. However, this new mild treatment causes a collapse of porosity 
rather than an amorphization, and therefore is suitable for mechanically fragile payloads. 
As our temperature-treatment process does not amorphisize the sample, we sought to 
determine if there was a morphological change in the material. Scanning electron microscopy 
(SEM) images in Figure 3 show the effect on morphology of various treatments during the 
loading and release process. The images of 150 nm NU-1000 prior to calcein loading (Figure 3a) 
and post-loading (Figure 3b) display no noticeable change in appearance compared with the 
temperature treated sample (Figure 3c). Figure 3d shows the MOF partway through the calcein 
release process. The morphology is significantly altered during the release process, which we 
attribute to degradation of the MOF by phosphate attack from PBS to the Zr-metal nodes.3 The 
same trends were observed for NU-901 (Figure S9). We performed further analysis to understand 
the degradation of the MOFs in PBS (Figure S10). 
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Figure 3. SEM Images of NU-1000 a) prior to calcein loading b) post-loading c) post-loading and 
temperature treatment and d) partway through calcein release process. Scale bars correspond to 400 nm. 
a.
b.
c.
d.
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Uptake of MOF by Hela cells 
In order to visualize the interaction of MOFs with live cells we utilized structured illumination 
microscopy (SIM). A super-resolution SIM microscope is the ideal tool for visualizing our drug-
delivery MOFs, since they have characteristic sizes at or below the 200 nm diffraction limit. 
Figures 4 and 5 show 3-color images of cells in the presence of 150 nm NU-1000 MOF, colored 
in green, with the nucleus colored in blue. Specific cellular vesicles are colored in magenta: in 
Figure 4, the magenta channel represents the lysosomes, whereas in Figure 5 it represents early 
endosomes. The lysosomes and endosomes in Figures 4 and 5, respectively, are stained to both 
help visualize cells and their intracellular organelle locations, and to show intracellular vesicles 
which could potentially contain MOF. These images show that the MOF has crossed the cell 
boundary, but it does not enter the nucleus. The cell visibly takes up NU-1000, as the magenta 
colored cellular organelles and green spots of MOF particles are in focus in the same plane.  
 
Figure 4. SIM 3-color image of HeLa cells demonstrating NU-1000 (150 nm) uptake into cellular 
boundary. Nucleus colored in blue, lysosomes colored in magenta, NU-1000 colored in green.  
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Figure 5. SIM 3-color image of HeLa cells demonstrating NU-1000 (150 nm) uptake into cellular 
boundary. Nucleus colored in blue, early endosomes colored in magenta, NU-1000 colored in green. 
To provide more evidence of MOFs taken up by cells, we utilized the optical sectioning 
capabilities of SIM to reconstruct a 3D image (for an animation, please see Supporting 
Information, File 2) showing the MOF nanoparticles clearly within the boundaries of the cell. 
Figure 6 shows a single slice of the 3D reconstruction, displaying an ellipsoid of stained 
lysosomes in magenta and, in particular, one green dot representing fluorescent MOF that is co-
located with the lysosome such that the color overlay has turned partially white. This verifies the 
internalization of the MOF within the cells. We conclude that cells can successfully take up the 
MOF nanoparticles and contain them inside the cell.  
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Figure 6. One slice of SIM 3D optical sectioning demonstrating NU-1000 (150 nm) internalization into 
HeLa cell, specifically bounded within cellular lysosome. Lysosomes colored in magenta, NU-1000 
colored in green. 
We exploited SIM’s high-speed super-resolution imaging capability to compare the dynamics 
of MOFs in both inter- and extracellular space. A 2-color 60-second time lapse video 
(Supporting Information, File 3) shows the movement of NU-1000 MOF in 8× real time. MOFs 
in the extracellular space move much more rapidly than those located within the cell. This can be 
explained by the difference in the mediums between the extracellular and intercellular space, 
which are DMEM and cytoplasmic fluid, respectively. This adds more evidence that the MOF is 
taken up by the cell, and supports the hypothesis that the MOFs could be contained in an 
organelle or vesicle, further restricting intercellular movement. 
In order to observe the uptake of our temperature-treated MOF by cells over an extended 
period of time, images of calcein-loaded temperature-treated NU-901 (cal@t.t.NU-901) with live 
HeLa cells were captured regularly over a period of 24 h, as shown in Figure 7. At t=0, 
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cal@t.t.NU-901 was added to a Lab-Tek well containing HeLa cells. Figure 7a shows that after 
30 minutes of incubation, no MOF had entered the cells; however it can be seen gathering on the 
cell boundaries. After 1 hour (Figure 7b), there is evidence that the cell has internalized some 
MOF. Between 2 and 8 hours gradually more MOF gathers at the cell boundary and enters the 
cell (Figures 7c-e), and after 24 hours, Figure 7f shows that the cell has taken up a large amount 
of MOF. All datasets were captured in 3D and can be viewed interactively online at 
http://fpb.ceb.cam.ac.uk/MOF/.49 Screenshots of the system in use for the 30 min and 24 h 
timepoints are shown in Figure 8. We hypothesized that the complexes situated around the 
cellular boundary will eventually be taken up through one of several potential endocytosis 
mechanisms, which could include active transport – clarithin-mediated endocytosis, caveolae-
mediated endocytosis, micropinocytosis, or clarithin and caveolae-independent-mediated 
endocytosis – rather than passive transport.50–53 Our experiments have shown that the uptake of 
MOF into the HeLa cells is not affected by the loading of the model drug calcein, nor by the 
temperature treatment process.  
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Figure 7 SIM images of HeLa cells incubated with calcein-loaded temperature-treated NU-901 
(cal@t.t.NU-901) at 30 min, 1 h, 2 h, 6 h, 8 h and 24 h. Lysosomes colored in magenta, cal@t.t.NU-901 
colored in green. These images are available at http://fpb.ceb.cam.ac.uk/MOF/ to view in interactive 3D.49 
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Figure 8. Screenshots of the interactive 3D system available at http://fpb.ceb.cam.ac.uk/MOF/.49 HeLa 
cells incubated with calcein-loaded temperature-treated NU-901 (cal@t.t.NU-901) at a) 30 min and 
c) 24 h.  
 
Endocytosis pathway studies 
To test our hypothesis regarding the mechanisms by which the MOF complex is taken up by the 
HeLa cells, we performed studies to analyze uptake with the addition of endocytosis 
pharmacological inhibitors. HeLa cells were incubated with either cal@NU-1000 or cal@t.t.NU-
901, the same two MOFs visualized with SIM. Figures 9 and 10 show the different levels of 
internal fluorescence, quantified by flow cytometry, in the presence of various pharmacological 
inhibitors. Sucrose and chlorpromazine are compounds which inhibit different stages of the 
clathrin-mediated endocytosis pathway. Sucrose inhibits endocytosis by trapping clathrin in 
microcages; chlorpromazine is believed to cause a loss of clathrin and the AP2 adaptor complex 
from the cell surface and artificial assembly on endosomal membranes.54,55 Nystatin inhibits the 
a.
b.
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functioning of the caveolae-mediated endocytosis pathway by creating aggregates to accumulate 
cholesterol that sequesters the lipid from membrane structures.55 The experiment was also run at 
4°C without inhibitors to check that uptake was occurring through active – and not passive – 
transport, because at this temperature it is known that active processes are inhibited.56  
 
Figure 9. Effects of different inhibitors on the uptake of cal@NU-1000 into HeLa cells. All samples were 
measured through flow cytometry and run in minimum of triplicates. Statistical significance was 
calculated through one-way analysis of variance (one-way ANOVA) and a post Dunnett’s Multiple 
Comparison Test compared to the Control, 37°C. (** P<0.01, **** P<0.0001) 
The calcein in the samples, upon release inside the cell after successful MOF uptake, was 
quantified by flow cytometry and normalized to a control uptake of cal@NU-1000 run at 37°C. 
The intrinsic fluorescence of the HeLa cells was found to be negligibly low, such that any 
measurement of fluorescence could be assumed to come from the calcein inside the cells 
(P<0.05). Figure 9 shows that low temperature caused a significant decrease in cellular 
fluorescence, demonstrating that active transport is necessary for taking up MOF complexes into 
HeLa cells. Incubation with sucrose as an inhibitor showed a ca. 49% decrease in fluorescence, 
indicating that affecting this part of the clathrin-mediated pathway was enough to perturb 
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particle uptake. Nystatin as an inhibitor caused a decrease in fluorescence by ca. 15%, also 
demonstrating the importance of the caveolae-mediated pathway in the uptake of these particles. 
Figure 10 shows the same endocytosis analysis using the cal@t.t.NU-901 particles as the 
nanocarrier. Again, the intrinsic fluorescence of HeLa cells was found to be negligibly low 
compared to calcein inside the cells (P<0.05). In low temperature conditions, the cell 
fluorescence was only ca. 42% of the control fluorescence, confirming the important role of 
active transport in internalizing MOFs. Incubation with sucrose showed no significant decrease 
in fluorescence, whereas incubation with chlorpromazine showed a ca. 16% decrease in 
fluorescence, indicating that for this MOF, a different part of the clathrin-mediated pathway was 
more important for particle uptake. We observe a decrease in fluorescence by ca. 33% when 
cells and cal@t.t.NU-901 are incubated with Nystatin, suggesting there is uptake occurring 
through the caveolae-mediated pathway.  
 
Figure 10. Effects of different inhibitors on the uptake of cal@t.t.NU-901 into HeLa cells. All samples 
were measured through flow cytometry and run in minimum of triplicates. Statistical significance was 
calculated through one-way analysis of variance (one-way ANOVA) and a post Dunnett’s Multiple 
Comparison Test compared to Control, 37°C. (* P<0.05, **** P<0.0001) 
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Taken as a whole, the endocytosis study shows that uptake of MOFs by HeLa cells can occur 
through different active transport mechanisms, depending on the surface chemistry, charge, and 
size of the MOF complex. For both the MOFs tested in this work, the caveolae-mediated 
pathway plays a significant role in cellular uptake. This information could be used in future 
design of MOFs as nanocarriers to maximize the amount of MOF taken up by the cells, thus 
ensuring the most effective targeted delivery of the drug.  
 
Therapeutic efficacy 
Having confirmed by SIM that large proportions of MOF are taken up by the cells in just 8 
hours, we altered the cargo loaded inside NU-901 and NU-1000 to deliver an anticancer 
therapeutic. The particular drug chosen was alpha-Cyano-4-hydroxycinnamic acid (α-CHC). 
This hydrophobic molecule has been suggested to prevent tumor growth because of its inhibition 
of monocarboxylate transporters (MCTs),57,58 which promote migration and invasion processes 
in cancer.59  
α-CHC was loaded into NU-901 (referred to as α-CHC@NU-901) and subsequently 
temperature treated (referred to α-CHC@t.t.NU-901) at 180 ̊C, as described earlier. Ion-coupled 
plasma-optical emission spectroscopy (ICP-OES) was used to measure loadings of 54.6 wt.% 
and 79.0 wt.% for α-CHC@NU-901 and α-CHC@t.t.NU-901, respectively. The anticancer drug 
was also loaded into NU-1000 (referred to as α-CHC@NU-1000) and temperature treated 
(referred to as α-CHC@t.t.NU-1000) in the same manner, producing loadings of 68.5 wt.% and 
81.0 wt.% for α-CHC@NU-1000 and α-CHC@t.t.NU-1000, respectively. TGA analysis showed 
that α-CHC does not degrade until ca. 230 ̊C (Figure S7), well above the 180 ̊C treatment 
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temperature, and should therefore retain its efficacy even when loaded into a temperature-treated 
MOF. 
We assessed the drug efficacy using a metabolic activity assay, where a lower value of cell 
viability indicates a greater efficacy of the drug. We measured the viability of cells in the 
presence of α-CHC on its own as a control (free drug), and with α-CHC loaded into both 
crystalline and temperature-treated MOF, to quantify the effectiveness of these MOFs at 
delivering the drug to cells. For the studies, set concentrations of loaded MOF were added to the 
solution, and the relative drug concentration was calculated based on the ICP loading 
measurements. Figure 11 shows the cell viability for α-CHC@NU-1000 and α-CHC@t.t.NU-
1000 after incubation for 8 h (Figure 11a) and 48 h (Figure 11b), as an indicator of drug efficacy. 
After just 8 hours, there is no significant difference in the efficacy between the crystalline and 
temperature-treated NU-1000. However, both profiles do indicate an efficacy that the free drug 
cannot achieve at 8 h, especially at drug concentrations above 0.5 mg/mL. Above this drug 
concentration, the MOF profiles show significant decline in cellular viability down to a final 
value of ca. 55% and ca. 44% viability for the highest tested drug concentration in α-CHC@NU-
1000 and α-CHC@t.t.NU-1000, respectively. Compared to the cellular viability of the free drug 
control, which stays at ca. 100% for all tested drug concentrations at 8 h, using NU-1000 to 
deliver α-CHC provides a more effective drug delivery.  
23 
 
 
Figure 11. MTS Assays measuring enzymatic metabolic activity for α-CHC-loaded NU-1000 in both 
crystalline and temperature treated complexes for a) 8 h and b) 48 h of in vitro incubation. The free drug, 
α-CHC Control, is shown incubated for both time points in yellow. Samples were run in minimum of four 
replicates. Standard errors are shown for each given concentration. 
After 48 h of incubation we observe a greater difference between the crystalline and 
temperature-treated NU-1000 profiles (Figure 11b). The temperature-treated sample showed an 
effect on cell viability even at the lowest tested drug concentration (0.2 mg/mL). As 
concentration is increased, the decline in cell viability continues steadily until no cells were 
detected as viable at a drug concentration of ca. 1.6 mg/mL. In contrast, the α-CHC@NU-1000 
did not cause a significant change in cell viability until ca. 0.7 mg/mL of drug concentration, 
showing a similar trend to the free drug control. There is no significant change in the crystalline 
profile for viability compared with the control until a drug concentration of 0.85 mg/mL, where 
the viability drops to ca. 20% and maintains this efficacy for all higher concentrations. We 
hypothesize that the difference between the crystalline and temperature-treated samples is 
because the crystalline sample had already released a significant amount of payload before 
entering the cell, and therefore this free drug is in the solution and does not enter the cell within 
the MOF. It is only at higher concentrations where there is more drug still left in the crystalline 
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framework – even after this burst release effect – where the drug can be effective at killing the 
cells. In contrast, the temperature-treated MOF inhibits the burst release effect, and therefore still 
retains much of its drug loading within the 48 h incubation time. Thus, when the cell takes up 
these particles, there is still a high payload delivery, and therefore a greater effect on cell 
viability.   
These same trends are observed in the 11 h (Figure 12a) and 48 h (Figure 12b) time points of 
the α-CHC@NU-901 and α-CHC@t.t.NU-901 in vitro studies. There is negligible difference 
between the effect of the crystalline and temperature-treated α-CHC-loaded MOF for the entirety 
of the drug concentration range tested after 11 h of incubation. However, both profiles do 
indicate significant efficacy compared to the free drug at concentrations higher than 0.4 mg/mL. 
The highest tested drug concentration in α-CHC@NU-901 and α-CHC@t.t.NU-901 (1.1 mg/mL 
and 1.6 mg/mL, respectively) yields cellular viability at ca. 30% after 11 hours. 
 
Figure 12. MTS Assays measuring enzymatic metabolic activity for α-CHC-loaded NU-901 in both 
crystalline and temperature treated complexes for a) 11 h and b) 48 h of in vitro incubation. The free drug 
control, α-CHC, is shown incubated for both time points in yellow. Samples were run in minimum of four 
replicates. Standard errors are shown for each given concentration. 
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After 48 h of incubation (Figure 12b), there is again a difference in the efficacy of crystalline 
versus temperature-treated MOFs. However, as also observed in the calcein release study (Figure 
2), the differences were less dramatic for NU-901 than NU-1000. Both the crystalline and 
temperature-treated samples showed a slight decline in cell viability at the lowest drug 
concentrations compared to the control. For drug concentrations up to 1 mg/mL, the anticancer 
drug shows better efficacy when loaded into the temperature-treated MOF. We attribute this to 
the same reasoning regarding suppression of the burst release effect that applied to α-
CHC@t.tNU-1000. 
Conclusions 
We have successfully developed an optimized protocol of treatment to delay the release of a 
model drug, calcein, from two Zr-based metal-organic frameworks, NU-1000 and NU-901. We 
utilized the surface tension of remaining aqueous solvent to collapse porosity when increasing 
the temperature, trapping the calcein within the framework. PXRDs of the temperature-treated 
MOF show lower peak intensity and peak broadening, which suggest partial degradation of the 
samples and decrease of crystallinity; however no morphological change can be seen on SEM 
images post-temperature treatment. Temperature treatment of MOFs with calcein loadings of 
over 35 wt.% can delay release of their payload compared to their crystalline forms by ca. 2-7 
days; complete release is not seen until ca. 30-49 days. We applied, for the first time, structured 
illumination microscopy (SIM) - a super-resolution microscopy technique - in order to visualize 
MOF uptake into HeLa cells. We can confirm intracellular presence through 3D optical 
sectioning and reconstruction, and time lapses evaluating dynamics of movement of particles 
intra- and extracellularly. Experiments with endocytosis inhibitors reveal that the MOF is taken 
up by the cells through active transport, although the exact endocytosis pathway depends on the 
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surface chemistry and other factors of the MOF. For both NU-1000 and NU-901, cellular uptake 
was reduced when the caveolae-mediate pathway was inhibited. Finally, we loaded the MOFs 
with the pharmacologically relevant anticancer drug α-CHC to show that efficacy is improved 
using temperature-treated MOFs as a drug delivery system, reaching loadings of up to 81 wt.%.  
Materials & Methods 
Materials 
NU-1000 (5 μm and 150 nm sizes), NU-901 (200 nm size), and their respective linker, 
H4TBAPy, was obtained via synthesis. Calcein disodium salt was purchased from Sigma-Aldrich 
(UK, 21030-5G-F). HeLa cells were obtained from the ATCC and cultured with Dulbecco’s 
modified Eagle’s medium (DMEM, Sigma Aldrich D5671), fetal bovine serum (FBS, Sigma 
Aldrich F9665), 100x 200 mM L-glutamine (Life Technologies 25030024), and penicillin and 
streptomycin (P-S, Life Technologies 15140122). Phosphate-Buffered Saline (PBS, Sigma 
D8537) and 1x trypsin–EDTA (Life Technologies 25300054) were purchased. Trypan blue, was 
purchased from Thermo Fisher (UK, 15250061). Stains for lysosomes, CellLight® Lysosomes-
RFP BacMam 2.0, early endosomes, CellLight® Early Endosomes-RFP BacMam 2.0, and 
nucleus, HCS NuclearMask™ Deep Red Stain (250X Concentrate in DMSO), were obtained 
from Thermo Fisher (UK, C10504, C10587, and H10294, respectively). Chlorpromazine 
hydrochloride (≥98%), Sucrose (≥99.5%), nystatin, and α-Cyano-4-hydroxycinnamic acid 
(≥98%, TLC, powder) was purchased from Sigma-Aldrich (UK). The CellTiter 96® AQueous 
Non-Radioactive Cell Proliferation Assay (MTS) was purchased from Promega (UK, G5421). 
All chemicals and biochemicals used were of analytical grade.  
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Synthesis 
NU-1000 (Figure S1) was produced through previously published protocols,60,61 which 
additionally describes the synthesis of the linker H4TBAPy.
41,60 5 μm-sized NU-1000 involved 
mixing ZrOCl2∙8H2O (388 mg, 1.20 mmol) and benzoic acid (10.8 g, 88.4 mmol) in DMF (32 
mL) and ultrasonically dissolving the mixture. The clear solution was incubated in an oven at 
80˚C for 1 h, and allowed to cool to room temperature. H4TBAPy (160 mg, 0.24 mmol) was 
added to this solution; the mixture was sonicated for 20 min. The yellow suspension was heated 
in an oven at 100˚C for 15.5 h and then allowed to cool to room temperature. The resulting 
material was isolated by centrifugation (7,750g for 5 min) and washed with DMF, activated with 
HCl (2 ml, 8 M solution), and subsequently washed with DMF again and acetone.  
For nano-sized (150 nm) NU-1000, 1 mL of 970 mg (3.00 mmol) of ZrOCl2∙8H2O and 16.0 g 
(131 mmol) of benzoic acid already dissolved in 80 mL of DMF in a 100 °C oven – was added to 
1 mL of 200 mg (0.300 mmol) of the ligand dissolved in 80 mL of DMF in a 100°C oven. The 
mixture contained 20 μL trifluoroacetic acid (0.26 mmol). The entire vial was then placed into an 
oven at 100°C for 1 h, and after cooling to room temperature, the suspension was isolated by 
centrifugation at 7800 rpm for 10 min. The sample was washed once with DMF, twice with 
acetone, and activated with HCl.  
To synthesize 200 nm NU-901, ZrOCl2 (97 mg) and para-aminobenzoic acid (1.5 g) were 
added into a 6-dram vial with 10mL of DMF. The solution was incubated at 80°C for 1 hour, and 
then allowed to cool to room temperature. H4TBAPy (40 mg) was added, and the mixture was 
heated at 100°C overnight. The resulting solid was separated by centrifugation, and extensively 
washed with DMF. The acid-activation with HCl (8 M, 0.5 mL) was performed with the sample 
suspended in DMF (13 mL). The vial was heated at 100 °C overnight and then was washed with 
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DMF before the solvent exchange with acetone. An N2 isotherm was performed after sample 
activation at 120 °C overnight. 
All MOFs were heat treated overnight, prior to experimental use, at 70°C in a vacuum oven 
overnight to remove any residue solvent. 
Characterization of Crystallinity 
Room temperature powder XRD (PXRD) was performed on both NU-901 and NU-1000 loaded 
and unloaded samples using a Bruker-D8 theta/theta machine with CuKα1 (λ = 1.5405 Å) 
radiation and a LynxEye position sensitive detector in Bragg Brentano parafocusing geometry. 
2θ steps ranged from 2 ̊ to 50 ̊. 
Characterization of Porosity 
Characterization through N2 adsorption was measured on either a TriStar II or 3Flex 
(Micromeritics) machine. For samples run on TriStar II, activation occurred in a sorption tube at 
120 °C for 12 h under vacuum on a SmartVacPrep (Micromeritics). For the samples run on 
3Flex, degassing occurring at 120 °C for 10 h. The nitrogen isotherm was measured from P/P0 = 
0 to 0.99 at 77 K (held by liquid nitrogen bath).  
Thermogravimetry 
Thermogravimetric analysis (TGA) was performed using a Perkin Elmer Pyris 1 thermal 
gravimetric analyzer, with the sample (ca. 1 mg) held on a platinum pan under a continuous flow 
of 20 mL/min N2 gas. TGA curves were obtained using a heating rate of 5 °C/min and measuring 
from 100 to 600 °C. 
Loading into MOFs 
To load calcein in the MOFs, 10 mg of either NU-1000 or NU-901 was soaked in a 10 mg/mL 
calcein in diH2O solution for 3 days in a 37 ̊C shaking incubator. After this initial load period, 
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the contents were centrifuged at 5400 g for 20-30 min and the supernatant was removed. The 
crystalline samples were then dried at 37 ̊C for 24 h. For the temperature treatment process, the 
samples were loaded into a high temperature vacuum oven at 180 ̊C for 24 h before use in drug 
release studies. To load α-CHC in the MOFs, 10 mg of either NU-1000 or NU-901 was soaked in 
a 5 mg/mL α-CHC in diH2O solution for 3 days in a 37 ̊C shaking incubator. The same post-
loading centrifugation and drying occurred for crystalline and temperature-treated samples as 
described above. All samples were washed once in PBS to remove any externally located 
payload. 
Release Study 
Release experiments were conducted over seven weeks at 37 ̊C in a shaking incubator. Samples 
of calcein-loaded MOF, in both crystalline and temperature-treated states, were loaded into 1.5 
mL Eppendorf tubes with 1 mL 1X PBS. At each time point, samples were removed from the 
37 ̊C shaking incubator, centrifuged at 16000  g for 50 s, and the supernatant was collected for 
UV-Vis absorbance measurement at 498 nm. The removed supernatant in the Eppendorf tubes 
was replaced with 1 mL fresh 1X PBS, and the samples were placed back into the shaking 
incubator at 37 ̊C until the following time point.  
Cell Culture 
HeLa cells were maintained at 37°C and 5% CO2 in high rich glucose (4500 mg/L) DMEM 
supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 units/mL penicillin and 100 μg/mL 
streptomycin. The cells were passaged three times a week (at about 80% confluency) at a density 
of 2.8 x 106 cell/cm2. 
Cellular Uptake prior to SIM 
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Cells were cultured before being seeded at a density of 50,000-75,000 on an 8-well Lab-Tek II 
Chambered Coverglass (ThermoFisher 155409) for approximately 8-12 hours. Cells were then 
incubated with either BacMam Lysosome Stain or BacMam Early Endosome Stain (depending 
on the experiment) overnight at a particles-per-cell (PPC) of 20-30. The following day, the entire 
well contents were removed and washed once with 1X PBS before incubation with 200 μL of 0.3 
mg/mL of MOF (150 nm NU-1000 or 200 nm cal@t.t.NU-901). After 4 hours, this solution was 
removed and washed once with 1x PBS, once with trypan blue, twice more with 1x PBS and 
then replaced with 200 μL of complete DMEM without phenol red. In experiments utilizing 3 
color SIM, nuclear stain was added prior to the trypan blue wash and allowed to incubate for 30 
min prior to removing and completing the remaining wash steps. For experiments using loaded 
MOF (cal@t.t.NU-901), time of incubation was specified as shown in SIM images; the 
subsequent wash steps were identical. 
SIM Imaging 
Images of the samples were collected using a custom built 3-color Structured Illumination 
Microscopy (SIM) setup which we have previously described.46 A 60X/1.2NA water immersion 
lens (UPLSAPO 60XW, Olympus) focused the structured illumination pattern onto the sample. 
This lens also captured the samples’ fluorescence emission light before imaging onto an sCMOS 
camera (C11440, Hamamatsu). Laser excitation wavelengths used were 488 nm (iBEAM-
SMART-488, Toptica), 561 nm (OBIS 561, Coherent), and 640 nm (MLD 640, Cobolt), to 
excite fluorescence emission of MOF, lysosomes or endosomes, and DNA, respectively. Images 
were acquired using custom SIM software previously published.46 Nine raw images were 
collected at each plane and recombined using a custom implementation of a Super-Resolution 
Optical Sectioning reconstruction algorithm.47  
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Endocytosis Experiments 
HeLa cells were cultured before being seeded on a 24-well plate at a density of 100,000 
cells/well for approximately 24 hours. Cells were then washed once with 1x PBS before a pre-
treatment 30 min incubation with different inhibitors or conditions: sucrose (150 μL, 0.3 M), 
chlorpromazine (150 μL, 100 μM), nystatin (150 μL, 0.250 mg/mL) all at 37˚C and untreated 
cells at 4˚C. After the 30 min pre-treatment with inhibitory conditions, the media was entirely 
removed and replaced with a solution of 0.5 mg MOF in each conditions (sucrose (150 μL, 0.3 
M), chlorpromazine (150 μL, 100 μM), nystatin (150 μL, 0.250 mg/mL), 4˚C media). The 
solution was incubated for 1.5 h at 37˚C, except for the condition incubated at 4˚C. After 
incubation, the well contents were removed and washed once with 1X PBS, once with trypan 
blue, twice more with 1x PBS, and then incubated for 5 min at 37˚C with trypsin. Fresh complete 
DMEM without phenol red was added to the wells after incubation and then contents were 
transferred to Eppendorf tubes and centrifuged at 1200 rpm for 5 min. The cells were re-
suspended in 200μL complete DMEM without phenol red. Samples were kept on ice until 
measurement on a Cytek DxP8 analyzer cytometer. Analysis was completed with FlowJo and 
Prism software. 
Cytotoxicity Analysis with Anticancer Drug 
HeLa cells were cultured before being seeded on a 96-well plate at a density of 7500 cells/well 
for approximately 24 hours. The compounds being tested (α-CHC loaded MOFs and the α-CHC 
free drug) were dissolved in complete DMEM at different concentrations. Cells were then 
washed once with 1x PBS before incubation at 37˚C/5% CO2 with the different concentrations of 
compounds for either 8, 11, or 48 h. After incubation, the well contents were removed and 
washed three to four times with 1X PBS. A solution of 100 μL of complete DMEM and 20 μL 
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MTS/phenazine methosulfate (20:1 ratio) was added to the wells and the contents were incubated 
for 1.5 h at 37˚C/5% CO2. The plates were read by a SPECTROstar Nano at 490 nm. 
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The following files are available free of charge: 
Supporting File #1. Structure of NU-1000 and NU-901, N2 adsorption isotherms at 77 K, and 
thermogravimetry curves under N2 atmosphere.  
Supporting File #2 (3Drotation_nNU1000 in HeLa cell): We reconstructed a 3D image using the 
optical sectioning capabilities of SIM showing a HeLa cell with NU-1000 located within its 
boundaries (file type: .qt). 
Supporting File #3 (Widefield Timelapse 2-color With Timestamp Faster-1_witharrow): We 
compared the dynamics of MOFs in both inter- and extracellular space with this 2-color 60-
second time lapse video showing the movement of NU-1000 in 8× real time (file type: .qt). 
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